Article
The current understanding on the impact of KRAS on colorectal cancer.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Aug 2021
Meng Mingjing, Zhong Keying, Jiang Ting, Liu Zhongqiu, Kwan Hiu Yee, Su Tao
Abstract excerpt
KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS mutations on the prognosis and survival of CRC patients drives many research studies to explore potential therapeutics or target therapy for the KRAS mutant CRC. This review summarizes the current understanding of the pathological consequences of...
Topics
- Animals
- Colorectal Neoplasms
- Humans
- Mutation
- Proto-Oncogene Proteins p21(ras)
